Evidence map›Paper›PMID 26349823›Full record

ArticleAntimicrobial agents and chemotherapy2015

Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?

Kristina Öbrink-Hansen, Rasmus Vestergaard Juul, Merete Storgaard, Marianne Kragh Thomsen, Tore Forsingdal Hardlei, Birgitte Brock, Mads Kreilgaard, Jakob Gjedsted

Registry-linked trialAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02306928 (Population Pharmacokinetics of Piperacillin in the Early Phase of Septic Shock - Does Standard Dosing Result in Therapeutic Plasma Concentrations?), which is not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02306928 completednot on this map

Population Pharmacokinetics of Piperacillin in the Early Phase of Septic Shock - Does Standard Dosing Result in Therapeutic Plasma Concentrations?

TypeobservationalSponsorUniversity of AarhusRan2014 to 2015Enrolled15ConditionsSeptic ShockArmsBlood draw
3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Observational
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Observational
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kristina Öbrink-HansenDepartment of Infectious Diseases, Aarhus University Hospital, Skejby, Denmark krisoebr@rm.dk.
Rasmus Vestergaard JuulDepartment of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
Merete StorgaardDepartment of Infectious Diseases, Aarhus University Hospital, Skejby, Denmark.
Marianne Kragh ThomsenDepartment of Clinical Microbiology, Aarhus University Hospital, Skejby, Denmark.
Tore Forsingdal HardleiDepartment of Clinical Biochemistry, Aarhus University Hospital, Skejby, Denmark.
Birgitte BrockDepartment of Clinical Biochemistry, Aarhus University Hospital, Skejby, Denmark.
Mads KreilgaardDepartment of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
Jakob GjedstedDepartment of Anesthesia and Intensive Care Medicine, Aarhus University Hospital, Skejby, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibiotic dosing in septic shock patients poses a challenge for clinicians due to the pharmacokinetic (PK) variability seen in this patient population. Piperacillin-tazobactam is often used for empirical treatment, and initial appropriate dosing is crucial for reducing mortality. Accordingly, we determined the pharmacokinetic profile of piperacillin (4 g) every 8 h, during the third consecutive dosing interval, in 15 patients treated empirically for septic shock. We developed a population pharmacokinetic model to assess empirical dosing and to simulate alternative dosing regimens and modes of administration. Time above the MIC (T>MIC) predicted for each patient was evaluated against clinical breakpoint MIC for Pseudomonas aeruginosa (16 mg/liter). Pharmacokinetic-pharmacodynamic (PK/PD) targets evaluated were 50% fT>4×MIC and 100% fT>MIC. A population PK model was developed using NONMEM, and data were best described by a two-compartment model. Central and intercompartmental clearances were 3.6 liters/h (relative standard error [RSE], 15.7%) and 6.58 liters/h (RSE, 16.4%), respectively, and central and peripheral volumes were 7.3 liters (RSE, 11.8%) and 3.9 liters (RSE, 9.7%), respectively. Piperacillin plasma concentrations varied considerably between patients and were associated with levels of plasma creatinine. Patients with impaired renal function were more likely to achieve predefined PK/PD targets than were patients with preserved or augmented renal function. Simulations of alternative dosing regimens showed that frequent intermittent bolus dosing as well as dosing by extended and continuous infusion increases the probability of attaining therapeutic plasma concentrations. For septic shock patients with preserved or augmented renal function, dose increment or prolonged infusion of the drug needs to be considered. (This study has been registered at ClinicalTrials.gov under registration no. NCT02306928.).

Indexed as

AgedAnti-Bacterial AgentsFemaleHumansMaleMicrobial Sensitivity TestsMiddle AgedMonte Carlo MethodPenicillanic AcidPiperacillinProspective StudiesPseudomonas aeruginosaShock, SepticTazobactamAnti-Bacterial AgentsPenicillanic AcidPiperacillinTazobactam

Identifiers

PMID26349823
PMCPMC4604352

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.